These Highlights Do Not Include All The Information Needed To Use Tafluprost Ophthalmic Solution Safely And Effectively. See Full Prescribing Information For Tafluprost Ophthalmic Solution.

Instructions for Use

Tafluprost(TA-floo-prost) ophthalmic solution 0.0015%

for topical ophthalmic use

Read these Instructions for Use before using your tafluprost ophthalmic solution and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment.

Important Information You Need to Know Before Using Tafluprost Ophthalmic Solution:

• Tafluprost ophthalmic solution is for the eye. Do not swallow tafluprost ophthalmic solution.
• Tafluprost ophthalmic solution single-dose containers are packaged in a foil pouch.
• Do not use the tafluprost ophthalmic solution single-dose containers if the foil pouch is already opened when you receive it.
• Write down the date you open the foil pouch in the space provided on the pouch.
• Use 1 drop of tafluprost ophthalmic solution in your affected eye or eyes each evening.
• If you use other eye medicines dropped into the eye (topically applied ophthalmic medicines), use each medicine at least 5 minutes apart from each other.

Follow these instructions every time you use tafluprost ophthalmic solution:

• If your healthcare provider has told you to use tafluprost ophthalmic solution drops in both eyes, repeat Steps 6 through 8 for your other eye.
• There is enough tafluprost ophthalmic solution in 1 single-dose container for both of your eyes.
• Throw away the opened single-dose container with any remaining tafluprost ophthalmic solution right away. Do not keep it to use it again even if there is product left in the container.To lessen the chance of infection, a new single-dose container must be opened each time you are ready to use tafluprost ophthalmic solution.
• Place the folded foil pouch back in the carton. The unopened single-dose containers must be used within 30 days after opening the foil pouch. Protect from moisture.

This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.

Manufactured by:

Micro Labs Limited

Bangalore – 560099, INDIA.

Manufactured for:

Micro Labs USA, Inc.

Somerset, NJ 08873

Rev. 03/2026

Risk Summary

There are no adequate and well-controlled studies of tafluprost administration in pregnant women to inform of drug-associated risks. In animal reproduction studies, intravenous administration of tafluprost to pregnant rabbits and rats throughout organogenesis resulted in embryofetal toxicities at exposures ≥5-times the human dose in rabbit and ≥2362-times the human dose in rat. (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Animal Data

In embryo-fetal development studies, intravenous administration of tafluprost to pregnant rats and rabbits during organogenesis caused increases in post-implantation losses in both species and reductions in fetal body weights in rats (≥0.03 mcg/kg/day in rabbits, 5-times the maximum clinical exposure based on C _max; ≥10 mcg/kg/day in rats, 2362-times the maximum clinical exposure based on C _max). Tafluprost also increased the incidence of vertebral skeletal abnormalities in rats and the incidence of skull, brain and spine malformations in rabbits at these same doses. In rats, there were no adverse effects on embryo-fetal development at a dose of 3 mcg/kg/day corresponding to maternal plasma levels of tafluprost acid that were 343 times the maximum clinical exposure based on C _max. At the no-effect dose in rabbits (0.01 mcg/kg/day), maternal plasma levels of tafluprost acid were below the lower level of quantification (20 pg/mL).

In a pre- and postnatal development study, intravenous administration of tafluprost to pregnant rats during organogenesis and through birth and lactation, caused increased mortality of newborns, decreased body weights and delayed pinna unfolding in offsprings. The no observed adverse effect level was at a tafluprost intravenous dose of 0.3 mcg/kg/day which is greater than 3 times the maximum recommended clinical dose based on body surface area comparison.

Risk Summary

There are no data on the presence of tafluprost or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production following topical ocular administration. Tafluprost and/or its metabolites are present in rat milk following ocular administration. When a drug is present in animal milk, it is likely that the drug will be present in human milk.

Tafluprost ophthalmic solution 0.0015% contains tafluprost, a fluorinated analog of prostaglandin F2α, for topical ophthalmic use. The chemical name for tafluprost is 1-methylethyl (5 Z)-7-{(1 R,2 R,3 R,5 S)-2-[(1 E)-3,3-difluoro-4-phenoxy-1-butenyl}-3,5-dihydroxycyclopentyl]-5-heptenoate.

The molecular formula of tafluprost is C ₂₅H ₃₄F ₂O ₅and its molecular weight is 452.53.

Its structural formula is:

Tafluprost is a colorless to light yellow viscous liquid that is practically insoluble in water.

Tafluprost ophthalmic solution is supplied as a sterile solution with a pH range of 5.5 to 6.7 and an Osmolality range of 260 to 300 mOsmol/kg.

Tafluprost ophthalmic solution contains Active: tafluprost 0.015 mg/mL; Inactives: edetate disodium, glycerin, monobasic sodium phosphate dihydrate, polysorbate 80,  hydrochloric acid and sodium hydroxide (to adjust pH) and water for injection.

Tafluprost ophthalmic solution does not contain a preservative.

Tafluprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as tafluprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of tafluprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long term effects of increased pigmentation are not known.

Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with tafluprost ophthalmic solution can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin F2α analogs. Tafluprost should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Use in pediatric patients is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.

In clinical studies up to 24 months in duration, patients with open-angle glaucoma or ocular hypertension and baseline pressure of 23 to 26 mmHg who were treated with tafluprost dosed once daily in the evening demonstrated reductions in intraocular pressure at 3 and 6 months of 6 to 8 mmHg and 5 to 8 mmHg, respectively.

None.

Tafluprost may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, color, thickness, shape and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.

Most common ocular adverse reaction is conjunctival hyperemia (4% to 20%). ( 6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Micro Labs USA Inc., at 1-855-839-8195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Contact lenses should be removed prior to the administration of tafluprost ophthalmic solution and may be reinserted 15 minutes after administration.

Absorption

Following instillation, tafluprost is absorbed through the cornea and is hydrolyzed to the biologically active acid metabolite, tafluprost acid. Following instillation of one drop of the 0.0015% solution once daily into each eye of healthy volunteers, the plasma concentrations of tafluprost acid peaked at a median time of 10 minutes on both Days 1 and 8. The mean plasma C _maxof tafluprost acid were 26 pg/mL and 27 pg/mL on Day 1, and Day 8, respectively. The mean plasma AUC estimates of tafluprost acid were 394 pg ^*min/mL and 432 pg ^*min/mL on day 1 and 8, respectively.

Elimination

Metabolism

Tafluprost, an ester prodrug, is hydrolyzed to its biologically active acid metabolite in the eye. The acid metabolite is further metabolized via fatty acid β-oxidation and phase II conjugation.

Mean plasma tafluprost acid concentrations were below the limit of quantification of the bioanalytical assay (10 pg/mL) at 30 minutes following topical ocular administration of tafluprost 0.0015% ophthalmic solution.

The recommended dosage is one drop in the conjunctival sac of the affected eye(s) once daily in the evening.

Tafluprost ophthalmic solution is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Tafluprost acid, a prostaglandin analog, is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.

• Pigmentation:Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent. ( 5.1)
• Eyelash Changes:Gradual changes to eyelashes including increased length, thickness and number of  lashes. Usually reversible. ( 5.2)

Apply one drop in the affected eye(s) once daily in the evening. ( 2)

Ophthalmic solution: 0.0015% tafluprost in a single-dose container.

Tafluprost should be used with caution in patients with active intraocular inflammation (e.g., iritis/uveitis) because the inflammation may be exacerbated.

The following adverse reactions have been identified during postapproval use of tafluprost. Because postapproval adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Respiratory disorders:exacerbation of asthma, dyspnea

Eye disorders:iritis/uveitis

In postmarketing use with prostaglandin analogs, periorbital and lid changes including deepening of the eyelid sulcus have been observed.

Use in pediatric patients is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use. ( 8.4)

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Preservative-containing or nonpreserved tafluprost 0.0015% was evaluated in 905 patients in five controlled clinical studies of up to 24-months duration. The most common adverse reaction observed in patients treated with tafluprost was conjunctival hyperemia which was reported in a range of 4% to 20% of patients. Approximately 1% of patients discontinued therapy due to ocular adverse reactions.

Ocular adverse reactions reported at an incidence of ≥ 2% in these clinical studies included ocular stinging/irritation (7%), ocular pruritus including allergic conjunctivitis (5%), cataract (3%), dry eye (3%), ocular pain (3%), eyelash darkening (2%), growth of eyelashes (2%) and vision blurred (2%).

Nonocular adverse reactions reported at an incidence of 2% to 6% in these clinical studies in patients treated with tafluprost 0.0015% were headache (6%), common cold (4%), cough (3%) and urinary tract infection (2%).

Tafluprost ophthalmic solution should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure (IOP) lowering effect.

Reduction of the intraocular pressure starts approximately 2 to 4 hours after the first administration with the maximum effect reached after 12 hours.

Tafluprost ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic product is being used, each one should be administered at least 5 minutes apart.

The solution from one single-dose container is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be maintained after the single-dose container is opened, discard the open single-dose container and the remaining contents immediately after administration.

Advise patients to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Potential for Pigmentation

Advise patients about the potential for increased brown pigmentation of the iris, which may be permanent. Also inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of tafluprost ophthalmic solution.

Potential for Eyelash Changes

Inform patients of the possibility of eyelash and vellus hair changes in the treated eye during treatment with tafluprost ophthalmic solution. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment.

Once Nightly Application

Advise patients to not exceed once daily dosing since more frequent administration may decrease the intraocular pressure lowering effect of tafluprost ophthalmic solution.

Handling the Single-Dose Container

Advise patients that tafluprost ophthalmic solution is a sterile solution that does not contain a preservative. The solution from one single-dose container is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be maintained after the single-dose container is opened, discard the open container and remaining contents immediately after administration. Open a new single-dose container every time you use tafluprost ophthalmic solution.

When to Seek Physician Advice

Advise patients that if they develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician's advice concerning the continued use of tafluprost ophthalmic solution.

Use with Other Ophthalmic Drugs

Advise patients if more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes between applications.

Storage Information

Instruct patients on proper storage of cartons, unopened foil pouches, and opened foil pouches [see How Supplied/Storage and Handling (16)].

Recommended storage for cartons and unopened foil pouches is to store refrigerated at 2° to 8°C (36° to 46°F). After the pouch is opened, the single-dose containers may be stored in the opened foil pouch for up to 30 days at room temperature 20° to 25°C (68° to 77°F). Protect from moisture.

Manufactured by:

Micro Labs Limited

Bangalore – 560099, INDIA.

Manufactured for:

Micro Labs USA, Inc.

Somerset, NJ 08873

Rev. 03/2026

Tafluprost ophthalmic solution 0.0015% is supplied as 0.3 mL a sterile solution in translucent low density polyethylene single-dose containers packaged in foil pouches (15 single-dose containers per pouch). Each single-dose container has 0.3 mL solution corresponding to 0.0045 mg tafluprost.

Unit-of-Use Carton of 15                                NDC 42571-264-26

Unit-of-Use Carton of 30                                NDC 42571-264-73

Unit-of-Use Carton of 90                                NDC 42571-264-74

Storage:

Store refrigerated at 2° to 8°C (36° to 46°F). During shipment tafluprost ophthalmic solution may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 2 days. Mail-order prescriptions received after two days of the dispensing date noted in the prescribing label should not be used. Store in the original pouch. After the pouch is opened, unopened single-dose containers may be stored in the opened foil pouch for up to 30 days at room temperature 20° to 25°C (68° to 77°F). Protect from moisture. Write down the date you open the foil pouch in the space provided on the pouch. Discard any unopened containers 30 days after first opening the pouch.

Tafluprost Ophthalmic Solution

0.0015%

0.3 mL Container label

For use in the eye

Rx Only

Rx Only

NDC 42571-264-93

Tafluprost Ophthalmic Solution

0.0015%

For Topical Application in the Eye

15 Single-dose Containers (0.3 mL each)

Single-dose Containers Perservative-Free, Sterile

NDC 42571-264-26

Rx Only

Tafluprost Ophthalmic Solution

0.0015%

For Topical Application in the Eye

REFRIGERATE (2° to 8°C or 36° to 46°F)

Single-dose Containers Perservative-Free, Sterile

15 Single-dose Containers (0.3 mL each)

Carcinogenesis

Tafluprost was not carcinogenic when administered subcutaneously daily for 24 months at doses up to 30 mcg/kg/day in rats and for 18 months at doses up to 100 mcg/kg/day in mice (over 1600 and 1300 times, respectively, the maximum clinical exposure based on plasma AUC).

Mutagenesis

Tafluprost was not mutagenic or clastogenic in a battery of genetic toxicology studies, including an in vitromicrobial mutagenesis assay, an in vitrochromosomal aberration assay in Chinese hamster lung cells, and an in vivomouse micronucleus assay in bone marrow.

Impairment of Fertility

In rats, no adverse effects on mating performance or fertility were observed with intravenous dosing of tafluprost at a dose of 100 mcg/kg/day (over 14000 times the maximum clinical exposure based on plasma C _maxor over 3600 times based on plasma AUC).

Risk Summary

There are no adequate and well-controlled studies of tafluprost administration in pregnant women to inform of drug-associated risks. In animal reproduction studies, intravenous administration of tafluprost to pregnant rabbits and rats throughout organogenesis resulted in embryofetal toxicities at exposures ≥5-times the human dose in rabbit and ≥2362-times the human dose in rat. (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Animal Data

In embryo-fetal development studies, intravenous administration of tafluprost to pregnant rats and rabbits during organogenesis caused increases in post-implantation losses in both species and reductions in fetal body weights in rats (≥0.03 mcg/kg/day in rabbits, 5-times the maximum clinical exposure based on C _max; ≥10 mcg/kg/day in rats, 2362-times the maximum clinical exposure based on C _max). Tafluprost also increased the incidence of vertebral skeletal abnormalities in rats and the incidence of skull, brain and spine malformations in rabbits at these same doses. In rats, there were no adverse effects on embryo-fetal development at a dose of 3 mcg/kg/day corresponding to maternal plasma levels of tafluprost acid that were 343 times the maximum clinical exposure based on C _max. At the no-effect dose in rabbits (0.01 mcg/kg/day), maternal plasma levels of tafluprost acid were below the lower level of quantification (20 pg/mL).

In a pre- and postnatal development study, intravenous administration of tafluprost to pregnant rats during organogenesis and through birth and lactation, caused increased mortality of newborns, decreased body weights and delayed pinna unfolding in offsprings. The no observed adverse effect level was at a tafluprost intravenous dose of 0.3 mcg/kg/day which is greater than 3 times the maximum recommended clinical dose based on body surface area comparison.

Risk Summary

There are no data on the presence of tafluprost or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production following topical ocular administration. Tafluprost and/or its metabolites are present in rat milk following ocular administration. When a drug is present in animal milk, it is likely that the drug will be present in human milk.

Tafluprost ophthalmic solution 0.0015% contains tafluprost, a fluorinated analog of prostaglandin F2α, for topical ophthalmic use. The chemical name for tafluprost is 1-methylethyl (5 Z)-7-{(1 R,2 R,3 R,5 S)-2-[(1 E)-3,3-difluoro-4-phenoxy-1-butenyl}-3,5-dihydroxycyclopentyl]-5-heptenoate.

The molecular formula of tafluprost is C ₂₅H ₃₄F ₂O ₅and its molecular weight is 452.53.

Its structural formula is:

Tafluprost is a colorless to light yellow viscous liquid that is practically insoluble in water.

Tafluprost ophthalmic solution is supplied as a sterile solution with a pH range of 5.5 to 6.7 and an Osmolality range of 260 to 300 mOsmol/kg.

Tafluprost ophthalmic solution contains Active: tafluprost 0.015 mg/mL; Inactives: edetate disodium, glycerin, monobasic sodium phosphate dihydrate, polysorbate 80,  hydrochloric acid and sodium hydroxide (to adjust pH) and water for injection.

Tafluprost ophthalmic solution does not contain a preservative.

Tafluprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as tafluprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of tafluprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long term effects of increased pigmentation are not known.

Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with tafluprost ophthalmic solution can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin F2α analogs. Tafluprost should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Use in pediatric patients is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.

In clinical studies up to 24 months in duration, patients with open-angle glaucoma or ocular hypertension and baseline pressure of 23 to 26 mmHg who were treated with tafluprost dosed once daily in the evening demonstrated reductions in intraocular pressure at 3 and 6 months of 6 to 8 mmHg and 5 to 8 mmHg, respectively.

None.

Tafluprost may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, color, thickness, shape and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.

Most common ocular adverse reaction is conjunctival hyperemia (4% to 20%). ( 6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Micro Labs USA Inc., at 1-855-839-8195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Instructions for Use

Tafluprost(TA-floo-prost) ophthalmic solution 0.0015%

for topical ophthalmic use

Read these Instructions for Use before using your tafluprost ophthalmic solution and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment.

Important Information You Need to Know Before Using Tafluprost Ophthalmic Solution:

• Tafluprost ophthalmic solution is for the eye. Do not swallow tafluprost ophthalmic solution.
• Tafluprost ophthalmic solution single-dose containers are packaged in a foil pouch.
• Do not use the tafluprost ophthalmic solution single-dose containers if the foil pouch is already opened when you receive it.
• Write down the date you open the foil pouch in the space provided on the pouch.
• Use 1 drop of tafluprost ophthalmic solution in your affected eye or eyes each evening.
• If you use other eye medicines dropped into the eye (topically applied ophthalmic medicines), use each medicine at least 5 minutes apart from each other.

Follow these instructions every time you use tafluprost ophthalmic solution:

• If your healthcare provider has told you to use tafluprost ophthalmic solution drops in both eyes, repeat Steps 6 through 8 for your other eye.
• There is enough tafluprost ophthalmic solution in 1 single-dose container for both of your eyes.
• Throw away the opened single-dose container with any remaining tafluprost ophthalmic solution right away. Do not keep it to use it again even if there is product left in the container.To lessen the chance of infection, a new single-dose container must be opened each time you are ready to use tafluprost ophthalmic solution.
• Place the folded foil pouch back in the carton. The unopened single-dose containers must be used within 30 days after opening the foil pouch. Protect from moisture.

This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.

Manufactured by:

Micro Labs Limited

Bangalore – 560099, INDIA.

Manufactured for:

Micro Labs USA, Inc.

Somerset, NJ 08873

Rev. 03/2026

Contact lenses should be removed prior to the administration of tafluprost ophthalmic solution and may be reinserted 15 minutes after administration.

Absorption

Following instillation, tafluprost is absorbed through the cornea and is hydrolyzed to the biologically active acid metabolite, tafluprost acid. Following instillation of one drop of the 0.0015% solution once daily into each eye of healthy volunteers, the plasma concentrations of tafluprost acid peaked at a median time of 10 minutes on both Days 1 and 8. The mean plasma C _maxof tafluprost acid were 26 pg/mL and 27 pg/mL on Day 1, and Day 8, respectively. The mean plasma AUC estimates of tafluprost acid were 394 pg ^*min/mL and 432 pg ^*min/mL on day 1 and 8, respectively.

Elimination

Metabolism

Tafluprost, an ester prodrug, is hydrolyzed to its biologically active acid metabolite in the eye. The acid metabolite is further metabolized via fatty acid β-oxidation and phase II conjugation.

Mean plasma tafluprost acid concentrations were below the limit of quantification of the bioanalytical assay (10 pg/mL) at 30 minutes following topical ocular administration of tafluprost 0.0015% ophthalmic solution.

The recommended dosage is one drop in the conjunctival sac of the affected eye(s) once daily in the evening.

Tafluprost ophthalmic solution is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Tafluprost acid, a prostaglandin analog, is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.

• Pigmentation:Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent. ( 5.1)
• Eyelash Changes:Gradual changes to eyelashes including increased length, thickness and number of  lashes. Usually reversible. ( 5.2)

Apply one drop in the affected eye(s) once daily in the evening. ( 2)

Ophthalmic solution: 0.0015% tafluprost in a single-dose container.

Tafluprost should be used with caution in patients with active intraocular inflammation (e.g., iritis/uveitis) because the inflammation may be exacerbated.

The following adverse reactions have been identified during postapproval use of tafluprost. Because postapproval adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Respiratory disorders:exacerbation of asthma, dyspnea

Eye disorders:iritis/uveitis

In postmarketing use with prostaglandin analogs, periorbital and lid changes including deepening of the eyelid sulcus have been observed.

Use in pediatric patients is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use. ( 8.4)

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Preservative-containing or nonpreserved tafluprost 0.0015% was evaluated in 905 patients in five controlled clinical studies of up to 24-months duration. The most common adverse reaction observed in patients treated with tafluprost was conjunctival hyperemia which was reported in a range of 4% to 20% of patients. Approximately 1% of patients discontinued therapy due to ocular adverse reactions.

Ocular adverse reactions reported at an incidence of ≥ 2% in these clinical studies included ocular stinging/irritation (7%), ocular pruritus including allergic conjunctivitis (5%), cataract (3%), dry eye (3%), ocular pain (3%), eyelash darkening (2%), growth of eyelashes (2%) and vision blurred (2%).

Nonocular adverse reactions reported at an incidence of 2% to 6% in these clinical studies in patients treated with tafluprost 0.0015% were headache (6%), common cold (4%), cough (3%) and urinary tract infection (2%).

Tafluprost ophthalmic solution should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure (IOP) lowering effect.

Reduction of the intraocular pressure starts approximately 2 to 4 hours after the first administration with the maximum effect reached after 12 hours.

Tafluprost ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic product is being used, each one should be administered at least 5 minutes apart.

The solution from one single-dose container is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be maintained after the single-dose container is opened, discard the open single-dose container and the remaining contents immediately after administration.

Advise patients to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Potential for Pigmentation

Advise patients about the potential for increased brown pigmentation of the iris, which may be permanent. Also inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of tafluprost ophthalmic solution.

Potential for Eyelash Changes

Inform patients of the possibility of eyelash and vellus hair changes in the treated eye during treatment with tafluprost ophthalmic solution. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment.

Once Nightly Application

Advise patients to not exceed once daily dosing since more frequent administration may decrease the intraocular pressure lowering effect of tafluprost ophthalmic solution.

Handling the Single-Dose Container

Advise patients that tafluprost ophthalmic solution is a sterile solution that does not contain a preservative. The solution from one single-dose container is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be maintained after the single-dose container is opened, discard the open container and remaining contents immediately after administration. Open a new single-dose container every time you use tafluprost ophthalmic solution.

When to Seek Physician Advice

Advise patients that if they develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician's advice concerning the continued use of tafluprost ophthalmic solution.

Use with Other Ophthalmic Drugs

Advise patients if more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes between applications.

Storage Information

Instruct patients on proper storage of cartons, unopened foil pouches, and opened foil pouches [see How Supplied/Storage and Handling (16)].

Recommended storage for cartons and unopened foil pouches is to store refrigerated at 2° to 8°C (36° to 46°F). After the pouch is opened, the single-dose containers may be stored in the opened foil pouch for up to 30 days at room temperature 20° to 25°C (68° to 77°F). Protect from moisture.

Manufactured by:

Micro Labs Limited

Bangalore – 560099, INDIA.

Manufactured for:

Micro Labs USA, Inc.

Somerset, NJ 08873

Rev. 03/2026

Tafluprost ophthalmic solution 0.0015% is supplied as 0.3 mL a sterile solution in translucent low density polyethylene single-dose containers packaged in foil pouches (15 single-dose containers per pouch). Each single-dose container has 0.3 mL solution corresponding to 0.0045 mg tafluprost.

Unit-of-Use Carton of 15                                NDC 42571-264-26

Unit-of-Use Carton of 30                                NDC 42571-264-73

Unit-of-Use Carton of 90                                NDC 42571-264-74

Storage:

Store refrigerated at 2° to 8°C (36° to 46°F). During shipment tafluprost ophthalmic solution may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 2 days. Mail-order prescriptions received after two days of the dispensing date noted in the prescribing label should not be used. Store in the original pouch. After the pouch is opened, unopened single-dose containers may be stored in the opened foil pouch for up to 30 days at room temperature 20° to 25°C (68° to 77°F). Protect from moisture. Write down the date you open the foil pouch in the space provided on the pouch. Discard any unopened containers 30 days after first opening the pouch.

Tafluprost Ophthalmic Solution

0.0015%

0.3 mL Container label

For use in the eye

Rx Only

Rx Only

NDC 42571-264-93

Tafluprost Ophthalmic Solution

0.0015%

For Topical Application in the Eye

15 Single-dose Containers (0.3 mL each)

Single-dose Containers Perservative-Free, Sterile

NDC 42571-264-26

Rx Only

Tafluprost Ophthalmic Solution

0.0015%

For Topical Application in the Eye

REFRIGERATE (2° to 8°C or 36° to 46°F)

Single-dose Containers Perservative-Free, Sterile

15 Single-dose Containers (0.3 mL each)

Carcinogenesis

Tafluprost was not carcinogenic when administered subcutaneously daily for 24 months at doses up to 30 mcg/kg/day in rats and for 18 months at doses up to 100 mcg/kg/day in mice (over 1600 and 1300 times, respectively, the maximum clinical exposure based on plasma AUC).

Mutagenesis

Tafluprost was not mutagenic or clastogenic in a battery of genetic toxicology studies, including an in vitromicrobial mutagenesis assay, an in vitrochromosomal aberration assay in Chinese hamster lung cells, and an in vivomouse micronucleus assay in bone marrow.

Impairment of Fertility

In rats, no adverse effects on mating performance or fertility were observed with intravenous dosing of tafluprost at a dose of 100 mcg/kg/day (over 14000 times the maximum clinical exposure based on plasma C _maxor over 3600 times based on plasma AUC).